This study reports that a combination of upadacitinib and oral minoxidil resulted in complete hair regrowth in a 20-year-old with alopecia universalis, Crohn's disease, and atopic dermatitis.
1 citations
,
January 2024 in “Curēus” This case study reported significant clinical improvement in a 26-year-old male with dissecting cellulitis of the scalp after treatment with upadacitinib, suggesting that JAK inhibitors may be a promising option for refractory cases, where standard treatments have limited success.
September 2026 in “Apollo Medicine” In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.
January 2026 in “Journal of Dermatology Research and Therapy” This case series found that topical janus kinase inhibitors, along with oral fexofenadine and vitamin D supplementation, significantly reduced disease severity in Black pediatric patients with alopecia areata, demonstrating substantial hair regrowth and minimal adverse side effects.
124 citations
,
October 2019 in “Frontiers in Immunology” This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.